Volume 76, Issue 11 (February 2019)
Tehran Univ Med J 2019, 76(11): 731-735 |
Back to browse issues page
1- Department of Microbiology, Faculty of Basic Sciences, Islamic Azad University, Qom Branch, Qom, Iran.
2- Department of Microbiology, School of Dentistry, Qom University of Medical Sciences, Qom, Iran. ,kabiri_10@yahoo.com
3- Department of Gynecology and Obstetrics, School of Medicine, Qom University of Medical Sciences, Qom, Iran.
2- Department of Microbiology, School of Dentistry, Qom University of Medical Sciences, Qom, Iran. ,
3- Department of Gynecology and Obstetrics, School of Medicine, Qom University of Medical Sciences, Qom, Iran.
Abstract: (2436 Views)
Background: Papilloma viruses are pathogenic double-strand DNA viruses that genotypes 16 and 18 are the cause of more than 50 percent of cancers as cervical cancer. Although vaccination is one of the best options for the papilloma cancer prevention but that is the most of world healthy problem, it is attempted to evaluate both naloxone (NLX) and alum mixture used as adjuvants together with HPV16 E7d vaccine to change the tumor microenvironment for the benefit of the immune system. The aim of this study was to investigate the effect of naloxone and alum mixture as adjuvants in HPV16 E7d vaccine on C57BL/6 female mouse in tumor microenvironment.
Methods: This study is a descriptive and cross-sectional study type, which was conducted on 80 case of C57BL/6 female mouse in Pasteur institute of Iran, Tehran over a period of six months in 2016. In this study, mice were vaccinated with dose of vaccine containing naloxone and alum mixture and alum as adjuvants and proper phosphate buffered saline (PBS) as control groups are considered. Tumor bearing mouse vaccinated by vaccine containing naloxone and alum mixture as adjuvants and phosphate buffered saline (PBS) as control group. Tumor model created through surgery and then tumor measurement done, the homogenate was created and protein concentration measured by Bradford system. Finally, assessment of IL-17, IL-4, IFN-γ and TGF-β cytokines concentration were performed by capture ELISA kit (mybiosource company) according to the company manual.
Results: It was observed that utilization of naloxone and alum mixture as adjuvant in the HPV16-E7d vaccine formulation significant reduction in the tumor growth (P≤0.0001) and reinforced meaningfully the cellular immunity reaction in tumor microenvironment.
Conclusion: The results of our study show that vaccine formulated with the naloxone and alum mixture as adjuvant in the HPV16-E7d vaccine increase the cellular immunity reaction on C57BL/6 female mouse in tumor microenvironment compared to phosphate buffered saline (PBS) control group in this new formulation as a papilloma viruses vaccine on C57BL/6 female mouse.
Methods: This study is a descriptive and cross-sectional study type, which was conducted on 80 case of C57BL/6 female mouse in Pasteur institute of Iran, Tehran over a period of six months in 2016. In this study, mice were vaccinated with dose of vaccine containing naloxone and alum mixture and alum as adjuvants and proper phosphate buffered saline (PBS) as control groups are considered. Tumor bearing mouse vaccinated by vaccine containing naloxone and alum mixture as adjuvants and phosphate buffered saline (PBS) as control group. Tumor model created through surgery and then tumor measurement done, the homogenate was created and protein concentration measured by Bradford system. Finally, assessment of IL-17, IL-4, IFN-γ and TGF-β cytokines concentration were performed by capture ELISA kit (mybiosource company) according to the company manual.
Results: It was observed that utilization of naloxone and alum mixture as adjuvant in the HPV16-E7d vaccine formulation significant reduction in the tumor growth (P≤0.0001) and reinforced meaningfully the cellular immunity reaction in tumor microenvironment.
Conclusion: The results of our study show that vaccine formulated with the naloxone and alum mixture as adjuvant in the HPV16-E7d vaccine increase the cellular immunity reaction on C57BL/6 female mouse in tumor microenvironment compared to phosphate buffered saline (PBS) control group in this new formulation as a papilloma viruses vaccine on C57BL/6 female mouse.
Type of Study: Original Article |
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |